全文获取类型
收费全文 | 2718篇 |
免费 | 177篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 57篇 |
妇产科学 | 122篇 |
基础医学 | 264篇 |
口腔科学 | 83篇 |
临床医学 | 354篇 |
内科学 | 602篇 |
皮肤病学 | 47篇 |
神经病学 | 134篇 |
特种医学 | 156篇 |
外科学 | 479篇 |
综合类 | 61篇 |
一般理论 | 22篇 |
预防医学 | 230篇 |
眼科学 | 26篇 |
药学 | 88篇 |
中国医学 | 1篇 |
肿瘤学 | 161篇 |
出版年
2022年 | 22篇 |
2021年 | 33篇 |
2020年 | 34篇 |
2019年 | 53篇 |
2018年 | 57篇 |
2017年 | 35篇 |
2016年 | 50篇 |
2015年 | 42篇 |
2014年 | 72篇 |
2013年 | 76篇 |
2012年 | 135篇 |
2011年 | 139篇 |
2010年 | 89篇 |
2009年 | 91篇 |
2008年 | 125篇 |
2007年 | 119篇 |
2006年 | 128篇 |
2005年 | 130篇 |
2004年 | 120篇 |
2003年 | 99篇 |
2002年 | 103篇 |
2001年 | 71篇 |
2000年 | 67篇 |
1999年 | 69篇 |
1998年 | 42篇 |
1997年 | 35篇 |
1996年 | 34篇 |
1995年 | 38篇 |
1994年 | 24篇 |
1993年 | 31篇 |
1992年 | 39篇 |
1991年 | 50篇 |
1990年 | 55篇 |
1989年 | 52篇 |
1988年 | 45篇 |
1987年 | 50篇 |
1986年 | 55篇 |
1985年 | 47篇 |
1984年 | 29篇 |
1983年 | 24篇 |
1981年 | 20篇 |
1980年 | 19篇 |
1979年 | 30篇 |
1978年 | 22篇 |
1977年 | 18篇 |
1976年 | 15篇 |
1975年 | 21篇 |
1974年 | 19篇 |
1973年 | 23篇 |
1972年 | 18篇 |
排序方式: 共有2902条查询结果,搜索用时 15 毫秒
81.
Clinical and patient‐reported outcomes of Chinese patients undergoing haemodialysis in hospital or in the community: A 1‐year longitudinal study
下载免费PDF全文
![点击此处可从《Nephrology (Carlton, Vic.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
82.
83.
Collin Lindsay J. Ross-Driscoll Katie Nash Rebecca Miller-Kleinhenz Jasmine M. Moubadder Leah Osborn Catherine Subhedar Preeti D. Gabram-Mendola Sheryl G. A. Switchenko Jeffrey M. Ward Kevin C. McCullough Lauren E. 《Annals of surgical oncology》2022,29(8):4739-4739
Annals of Surgical Oncology - 相似文献
84.
85.
86.
Developments during the past few years have resulted in multiple kinds of platelet products for transfusion. This involves different collection methods, containers, preservative solutions, modifications of storage temperatures and durations, and additional treatments such as pathogen reduction. Much experience has been obtained testing these processes in vitro to seek indications of in vivo effectiveness. Availability of an in vitro method that correlated with in vivo effectiveness would be extremely valuable for these different kinds of platelet products and as more innovation in platelet preparation occurs in the future. This report reviews the methods for in vitro platelet testing with a view to their in vivo implications and whether such testing could be helpful in projecting the clinical effectiveness of different platelet products. 相似文献
87.
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial 总被引:9,自引:1,他引:9
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
McCullough J Vesole DH Benjamin RJ Slichter SJ Pineda A Snyder E Stadtmauer EA Lopez-Plaza I Coutre S Strauss RG Goodnough LT Fridey JL Raife T Cable R Murphy S Howard F Davis K Lin JS Metzel P Corash L Koutsoukos A Lin L Buchholz DH Conlan MG 《Blood》2004,104(5):1534-1541
We report a transfusion trial of platelets photochemically treated for pathogen inactivation using the synthetic psoralen amotosalen HCl. Patients with thrombocytopenia were randomly assigned to receive either photochemically treated (PCT) or conventional (control) platelets for up to 28 days. The primary end point was the proportion of patients with World Health Organization (WHO) grade 2 bleeding during the period of platelet support. A total of 645 patients (318 PCT and 327 control) were evaluated. The primary end point, the incidence of grade 2 bleeding (58.5% PCT versus 57.5% control), and the secondary end point, the incidence of grade 3 or 4 bleeding (4.1% PCT versus 6.1% control), were equivalent between the 2 groups (P =.001 by noninferiority). The mean 1-hour posttransfusion platelet corrected count increment (CCI) (11.1 x 10(3) PCT versus 16.0 x 10(3) control), average number of days to next platelet transfusion (1.9 PCT versus 2.4 control), and number of platelet transfusions (8.4 PCT versus 6.2 control) were different (P <.001). Transfusion reactions were fewer following PCT platelets (3.0% PCT versus 4.4% control; P =.02). The incidence of grade 2 bleeding was equivalent for PCT and conventional platelets, although posttransfusion platelet count increments and days to next transfusion were decreased for PCT compared with conventional platelets. 相似文献
88.
Kalhan SC Bugianesi E McCullough AJ Hanson RW Kelley DE 《Metabolism: clinical and experimental》2008,57(3):305-312
Glyceroneogenesis, that is, formation of triglyceride-glycerol from pyruvate, is a critical component of triglyceride fatty acid cycling in vivo. The quantitative contribution of glyceroneogenesis to triglyceride-glycerol and its hormonal regulation have not been examined in humans. We have quantified the contribution of pyruvate to very low-density lipoprotein (VLDL) triglycerides in subjects with type 2 diabetes mellitus using the deuterium labeling of body water technique. Subjects with type 2 diabetes mellitus were studied before and after a 6-month behavioral intervention therapy, during fasting and during a hyperinsulinemic normoglycemic clamp. Response to glucagon infusion was examined in 5 healthy subjects after an overnight fast. Glyceroneogenesis contributed approximately 54% to VLDL triglyceride-glycerol in type 2 diabetes mellitus as compared with approximately 12% contribution of plasma glucose. There was no effect of insulin plus glucose during hyperinsulinemic clamp on glyceroneogenesis even after clinical interventions, when insulin sensitivity had improved. In healthy subjects, the contribution of triosephosphates to plasma VLDL triglycerides was approximately 45%. Glyceroneogenesis, in contrast to glycolysis, is the predominant source of triglyceride-glycerol carbon for VLDL triglycerides in subjects with type 2 diabetes mellitus. The contribution of glyceroneogenesis to triglyceride-glycerol is not affected by short (4 hours) infusion of insulin in type 2 diabetes mellitus. 相似文献
89.
90.
In vivo release and turnover of secreted platelet antiheparin proteins in rhesus monkey (Macaca mulatta) 总被引:1,自引:0,他引:1
Musial J; Niewiarowski S; Edmunds LH Jr; Addonizio VP Jr; Nicolaou KC; Colman RW 《Blood》1980,56(4):596-607
Human and rhesus monkey platelets secrete at least two antiheparin proteins: platelet factor 4 (PF4) and low affinity platelet factor 4 (LA-PF4). Neither of these proteins showed species-related antigenic differences. As determined by radioimmunoassay, the levels of PF4 and LA-PF4 antigen per 10(9) monkey platelets amounted to 10.7 and 20.3 microgram, respectively. One milliliter of monkey plasma prepared from blood collected into an anticoagulant composed of EDTA, prostaglandin E1, and theophylline solution contained 22.4 ng LA-PF4 and 8.0 ng PF4. Concentrations of these two platelet-specific proteins in monkeys closely resembled levels found in human platelets and plasma. Infusion of prostacyclin (PGI2) (100 or 300 ng/kg/min) into monkeys for 15 min resulted in a significant decrease of plasma levels of LA-PF4 antigen and of PF4 by 40%--60% (p < 0.0001). This decrease was related to the inhibitory effect of PGI2 on the secretion of platelets stimulated by a catheter or by venipuncture. Longer infusion of PGI2 did not produce further significant change. The supernate obtained after aggregation of human platelets stimulated by thrombin was injected into monkeys receiving PGI2 infusion. The disappearance of LA-PF4 antigen in monkey plasma followed a biphasic exponential curve with half-lives for the fast and slow components of 8.4 and 63 min. PF4 disappeared faster but followed the same pattern (half-lives for the fast and slow component of 2.1 and 70 min). Analysis of the experimental data suggests that the low levels of secreted platelet proteins in monkey plasma are related to their minimal in vivo release and to their rapid clearance. 相似文献